Research Articles - Macular Degeneration
- The clinical path for an innovative gene therapy designed to restore vision in people with a wide range of advanced retinal diseases is clearer thanks to a productive discussion with the U.S. Food and Drug Administration (FDA) about development plans. RetroSense Therapeutics, the company developing the gene therapy, and the Foundation Fighting Blindness, a funding partner, met with the FDA earlier this week to get feedback on plans to submit an Investigational New Drug (IND) application for launching a clinical trial of the treatment. Known as a pre-IND meeting, the discussion covered
A key to survival for any organism, plant or animal, is energy. And, in humans, every cell gets its energy from a tiny, organ-like structure called a mitochondrion. It operates like a power plant, providing the energy needed to stay alive and functioning. Among their many functions, mitochondria combine sugar and oxygen, which serve as the cells’ supply of fuel.
One consequence of most retinal degenerations, including retinitis pigmentosa and macular degeneration, is that mitochondria operate at reduced capacity,
The IMT provides improved central and detailed vision by focusing and magnifying images onto the functional, outer regions of the recipient’s retina. People with advanced AMD normally experience degeneration of the macula or central region of the retina.
In clinical studies, the device has helped people improve their ability to read, recognize faces, and perform other detailed-oriented tasks. In a 219-participant study, 75 percent of recipients had their level of vision improved from severe impairment to moderate impairment.
Owings Mills, MD — An innovative technology, employing a tiny capsule implanted in the eye, is stabilizing vision in people suffering from dry age-related macular degeneration (AMD). Encapsulated Cell Technology (ECT), developed by Rhode Island-based Neurotech, preserved vision in a majority of the 51 people who participated in a Phase II clinical trial.
There are currently no treatments for dry AMD, which is a leading cause of blindness for people 55 and older in developed countries.
- An emerging low-radiation treatment for wet age-related macular degeneration (AMD) known as Oraya Therapy™ reduced the number of Lucentis™ injections that people receive for the treatment of recurring wet AMD. In Oraya’s 230-person, Phase II/III clinical trial across Europe, the treatment reduced the need for Lucentis injections by 32 percent.
- A 21,000-participant study suggests that moderate alcohol consumption — more than one drink per day — increases the risk of early age-related macular degeneration (AMD) by 20 percent and advanced AMD by 44 percent. The report in the American Journal of Epidemiology was authored by investigators from the Centre for Eye Research Australia.
The research team says that, until its study, there was little evidence
Researchers have determined that a common blood test for assessing cardiovascular disease risk can also indicate risk for age-related macular degeneration (AMD). They found that people with high levels of high-sensitivity C-reactive protein (hsCRP) — a biomarker for inflammation related to heart disease, cancer and other conditions — have a 49 percent greater risk of all forms of AMD compared to those with low levels of hsCRP. High levels of hsCRP are also associated with an 84 percent increased
A groundbreaking treatment for retinal degenerations is poised to become the second-ever stem cell therapy to move into a Phase I/II clinical trial. The company StemCells, Inc. (SCI), has received authorization from the FDA to launch a clinical trial of its neural stem cell treatment for people with the dry age-related macular degeneration (AMD).
SCI’s announcement came 10 days after Advanced Cell Technology (ACT), which
- An international team of researchers was able to temporarily restore some vision in blind mice by treating their retinas with a chemical called acrylamide-azobenzene-quaternary ammonium (AAQ). While the research is still at an early stage, AAQ, or a derivative, might be used someday to restore vision in people who are blind from advanced retinal degenerations, such as retinitis pigmentosa (RP) or age-related macular degeneration.
- To help people with retinal degenerative diseases better understand issues related to cataracts and their removal, Foundation-funded clinicians Richard Weleber, M.D., of the Casey Eye Institute, Oregon Health & Science University, and Jacque Duncan, M.D., of the University of California, San Francisco, provide the following answers to commonly asked questions: